Qureight and biopharmaceutical company Remedy Cell have agreed a partnership to validate RC-0315’s mechanism of action in idiopathic pulmonary fibrosis (IPF). The primary objective of the RC-0315 Phase Ib clinical study is to measure drug safety and tolerability. The study’s exploratory objectives will assess the… Read More
Persica Pharmaceuticals has announced positive topline data from its Phase Ib Modic Trial for PP353, a drug candidate with the potential to offer patients an alternative to long-term opioid use for pain relief by targeting the cause of the pain rather than the symptoms. The trial is… Read More
Precision BioSciences has announced positive initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial. The ELIMINATE-B trial is designed to investigate PBGENE-HBV at multiple ascending dose levels with three dose administrations per dose level… Read More
Allogene Therapeutics has been given the green light from the US Food and Drug Administration (FDA) for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR-T product. The Phase I RESOLUTION basket trial will evaluate the safety and preliminary efficacy of ALLO-329 in patients with systemic lupus erythematosus, including… Read More
Avacta has announced positive early efficacy data for its peptide drug conjugate, AVA6000, demonstrating clinically meaningful tumour shrinkage in patients with salivary gland cancer (SGC). AVA6000 consists of doxorubicin chemotherapy conjugated with Avacta’s pre|CISION peptide, specifically cleaved by fibroblast activation protein-alpha (FAP) in the tumour microenvironment. Read More
Synthekine has announced positive initial results from a Phase I study of SYNCAR-001 + STK-009 for the treatment of relapsed or refractory CD19+ haematologic malignancies. In the results presented from eight patients treated in the dose escalation portion of the study with a fixed SYNCAR-001 infusion of… Read More
A clinical trial has launched in China of ESO-T01, an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into BCMA CAR-T cells, for the treatment of multiple myeloma. The proof-of-concept, first-in-human trial is underway and initial clinical data are expected to be presented… Read More
Everest Medicines has revealed positive results in the ongoing Phase Ib/IIa clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011). In an analysis of the data, results from the trial showed that for patients in the low-dose cohort who have… Read More
The latest episode of the DDW Highlights podcast is now available. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s leading news stories all feature early-stage clinical trials, including a short interfering RNA for cardiovascular disease,… Read More
News round-up for 25-29 November by DDW Senior Digital Content Editor Diana Spencer. This week’s leading news stories all feature early-stage clinical trials, including a short interfering RNA for cardiovascular disease, a new type of drug for type 2 diabetes, a gene therapy for Duchenne muscular dystrophy, a… Read More
Ark Biopharmaceutical (ArkBio) says it has successfully dosed all participants in a Phase I clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. The treatment offers a potential a new option for preventing RSV infection for vulnerable infants susceptible… Read More
SCG Cell Therapy has announced late-breaking data from its Phase I trial of SCG101, a first-in-class autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T cell (TCR-T) therapy targeting hepatitis B surface antigen (HBsAg). The data was presented at the 2024 AASLD Liver Meeting in San Diego, United… Read More
Immunotherapy company Vittoria Biotherapeutics has successfully completed a $25 million private financing round. This funding is a $10 million extension to its previous $15 million financing secured in November 2023. The latest round was led by Valley Forge Investment Corporation, with new investments from the Global BioAccess Fund and Hatch… Read More
Precision BioSciences has announced it will commence a Phase I clinical trial for its in vivo gene editing programme PBGENE-HBV, following Clinical Trial Application (CTA) approval in Moldova. PBGENE-HBV is designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicating hepatitis B… Read More
The first patient has been dosed with PFL-002/VERT-002 in a Phase I/II first-in-human trial for patients with non-small cell lung cancer (NSCLC) with MET alterations. PFL-002/VERT-002 is a monoclonal antibody acting as a degrader of c-MET. MET, also known as hepatocyte growth factor receptor… Read More
Misetionamide (GP-2250) in combination with gemcitabine has demonstrated a good safety profile and potential therapeutic benefit in the treatment of pancreatic adenocarcinoma. Panavance Therapeutics revealed the interim data from its Phase I clinical study at the 2024 Visceral Medicine Congress in Leipzig, Germany. The… Read More
